Manipal Health Enterprises Limited has confirmed that Sathish K R continues to serve as its Compliance Officer, a position he has held since November 25, 2025. The disclosure, filed with the Bombay Stock Exchange and National Stock Exchange on August 5, 2026, ensures transparency regarding the company’s adherence to regulatory governance standards. This continuity in the compliance function supports the company’s ongoing commitment to maintaining robust corporate governance frameworks as mandated by market regulators.

The intimation was submitted under Regulation 6(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Additionally, the filing incorporates details required under SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/1/3762/2026, dated January 30, 2026. These regulatory references underscore the structured approach the company takes toward statutory disclosures and compliance officer appointments.

Sathish K R, who holds ICSI Membership No. A15203, serves concurrently as the Company Secretary and General Counsel of Manipal Health Enterprises Limited. He has been associated with the company since August 14, 2019, overseeing regulatory strategy, legal compliance, and corporate governance functions. His dual role ensures integrated oversight of legal and compliance matters within the organization.

With over 25 years of experience in legal, company secretarial, and compliance domains, Sathish K R brings extensive industry knowledge to his role. He holds a bachelor’s degree in law from Bengaluru University and a master’s degree in law with distinction in commercial and corporate law from Queen Mary and Westfield College, University of London. Prior to joining Manipal Health Enterprises Limited, he worked with prominent organizations including Bosch Limited, GE Bayer Silicones (India) Private Limited, Essilor Manufacturing India Private Limited, and Siemens VDO Automotive Limited.

Governance Continuity

The retention of Sathish K R as Compliance Officer reflects stability in the company’s governance structure. His long-standing association with the firm since 2019 provides institutional memory and consistent interpretation of evolving regulatory requirements. For investors, this continuity signals a mature compliance infrastructure capable of navigating complex regulatory landscapes without disruption. The explicit mention of his qualifications and prior experience in the filing further reinforces the credibility of the company’s internal controls.

Manipal Health Enterprises Limited has adopted a Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information (UPSI) to comply with Regulation 8(1) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015. The filing, submitted to the BSE and NSE on August 5, 2026, outlines a framework designed to ensure uniformity, transparency, and fairness in dealings with all stakeholders while preventing selective disclosure of material events. The adoption of this Code is a procedural requirement preceding the company’s public listing, ensuring that price-sensitive information is disseminated promptly and universally to maintain market integrity.

The Code designates specific roles for oversight, including a Chief Investor Relations Officer (CIRO) and a Compliance Officer. The CIRO is responsible for ensuring the uniform dissemination of information, monitoring compliance with disclosure timelines, and assessing the materiality of information in consultation with senior management. The Compliance Officer oversees the maintenance of records, monitors adherence to UPSI preservation rules, and ensures timely reporting of shareholding changes. Both officers work together to review disclosure controls and educate employees on regulatory requirements.

Key Provisions of the Disclosure Framework

The Code establishes strict protocols for handling Unpublished Price Sensitive Information to avoid selective disclosure. Key operational guidelines include:

The policy emphasizes that any inadvertent leakage of information triggers an immediate obligation to make that information generally available. The CIRO must consult the CEO, Whole-time Director, or CFO before responding to queries regarding market rumors, ensuring that all public announcements are accurate and compliant with SEBI’s Listing Obligations and Disclosure Requirements Regulations, 2015.

Handling Legitimate Business Purposes

Recognizing that UPSI may need to be shared for legitimate business purposes, the Code defines “legitimate purpose” to include sharing information with partners, lenders, auditors, legal advisors, and regulators in the ordinary course of business. Such sharing is permitted only if it does not evade insider trading prohibitions. Recipients of UPSI must sign confidentiality agreements acknowledging their status as insiders and agreeing not to trade in the company’s securities while in possession of such information. The Company must obtain detailed identifiers, including PAN numbers, for all recipients and maintain a structured digital database of these interactions.

Effective Date and Regulatory Context

The Code becomes effective from the date of approval of the Draft Red Herring Prospectus by the Board. This timing aligns with the company’s transition towards public listing, where rigorous disclosure standards are mandatory. The Board reserves the right to review and amend the Code to remain consistent with evolving statutory and regulatory directions. The submission of this Code under Regulation 8(2) of the PIT Regulations serves as formal intimation to the stock exchanges, ensuring that the regulatory framework for fair disclosure is in place before the commencement of public trading.